Frank, Martin <br/><br/>
Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.  [electronic resource] 

 -  PharmacoEconomics  Mar 2013 
 - 215-28 p.  digital 
<br/><br/> Publication Type: Journal Article; Review; Systematic Review 
<br/><br/><label>ISSN: </label>1179-2027 
<br/><br/><label>Standard No.: </label>10.1007/s40273-012-0017-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Cost-Benefit Analysis<br/>ErbB Receptors--antagonists & inhibitors<br/>Genetic Markers<br/>Genetic Testing--economics<br/>Health Care Costs<br/>Humans<br/>Mutation<br/>Neoplasm Metastasis<br/>Pharmacogenetics<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Treatment Outcome<br/>ras Proteins--genetics